V2 vasopressin receptor mutations

被引:14
|
作者
Makita, Noriko [1 ]
Manaka, Katsunori [1 ]
Sato, Junichiro [1 ]
Iiri, Taroh [1 ,2 ]
机构
[1] Univ Tokyo, Dept Endocrinol & Nephrol, Tokyo, Japan
[2] St Marianna Univ, Sch Med, Dept Pharmacol, Kawasaki, Kanagawa, Japan
来源
VASOPRESSIN | 2020年 / 113卷
关键词
NEPHROGENIC DIABETES-INSIPIDUS; PROTEIN-COUPLED RECEPTOR; FUNCTIONAL-CHARACTERIZATION; INAPPROPRIATE ANTIDIURESIS; URINARY CONCENTRATION; SURFACE EXPRESSION; AVPR2; MUTATIONS; X-INACTIVATION; GENE; MUTANT;
D O I
10.1016/bs.vh.2019.08.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
V2 vasopressin receptor (V2R) is a member of the G protein-coupled receptor (GPCR) family in which many disease-causing mutations have been identified and thus generated much interest. Loss-of-function V2R mutations cause nephrogenic diabetes insipidus (NDI) whereas gain-of-function mutations cause nephrogenic syndrome of inappropriate antidiuresis (NSIAD). The mechanisms underlying a V2R loss-of-function can be theoretically classified as either protein expression, localization (ER retention) or functional disorders. Functional analyses have revealed however that these mechanisms are likely to be complex. Strikingly, V2Rmutations at the same site can result in opposite phenotypes, e.g., R137H and R137L/C cause NDI and NSIAD, respectively. These findings support the notion that the constitutive activation of GPCRs might be often associated with their instability and denaturation. Thus, functional analysis of disease-causing V2R mutations may not only reveal potential new treatment strategies using pharmacochaperones for NDI and inverse agonists for NSIAD, but also provide a greater understanding of the physiological functions of GPCRs and highlight the new paradigms, i.e., biased agonism and protean agonism.
引用
收藏
页码:79 / 99
页数:21
相关论文
共 50 条
  • [1] The V2 vasopressin receptor mutations and fluid homeostasis
    Birnbaumer, M
    [J]. CARDIOVASCULAR RESEARCH, 2001, 51 (03) : 409 - 415
  • [2] Gain-of-function mutations in the V2 vasopressin receptor
    Rosenthal, Stephen M.
    Gitelman, Stephen E.
    Vargas, Gabriel A.
    Feldman, Brian J.
    [J]. HORMONE RESEARCH, 2007, 67 : 121 - 125
  • [3] Functional characterization of five V2 vasopressin receptor gene mutations
    Wenkert, D
    Schoneberg, T
    Merendino, JJ
    Pena, MSR
    Vinitsky, R
    Goldsmith, PK
    Wess, J
    Spiegel, AM
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1996, 124 (1-2) : 43 - 50
  • [4] Vasopressin V2 receptor antagonists
    Wong, LL
    Verbalis, JG
    [J]. CARDIOVASCULAR RESEARCH, 2001, 51 (03) : 391 - 402
  • [5] Phosphorylation of the V2 vasopressin receptor
    Innamorati, G
    Sadeghi, H
    Eberle, AN
    Birnbaumer, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (04) : 2486 - 2492
  • [6] Vasopressin V2 receptor antagonists
    Verbalis, JG
    [J]. JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2002, 29 (01) : 1 - 9
  • [7] Influence of vasopressin V2 receptor gene mutations on splicing and mRNA stability
    Oksche, A
    Kuhn, R
    Dickson, J
    Rosenthal, W
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (04) : 198 - 198
  • [8] Analysis of the effects of vasopressin V2 receptor nonsense mutations on mRNA turnover
    Oksche, A
    Kuhn, R
    Schuelein, R
    Rosenthal, W
    [J]. FASEB JOURNAL, 1997, 11 (09): : A959 - A959
  • [9] Tolvaptan, Vasopressin V2 Receptor Antagonist
    Inomata, Takayuki
    [J]. JOURNAL OF CARDIAC FAILURE, 2010, 16 (09) : S135 - S135
  • [10] Vasopressin V2 Receptor/Bioligand Interactions
    Cezary Czaplewski
    Rajmund Kaźmierkiewicz
    Jerzy Ciarkowski
    [J]. Letters in Peptide Science, 1998, 5 : 333 - 335